(secondQuint)Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma.

 This is a dose escalation, phase 1/2a study to assess the safety and tolerability of PVX-410, (a multi-peptide cancer vaccine), treatment regimen in patients with smoldering multiple myeloma as a single agent and in combination with lenalidomide.

.

 Approximately 22 patients will receive six (6) bi-weekly, subcutaneous injections of PVX-410 for a total of twelve (12) weeks of treatment.

 Safety will be monitored throughout the study.

 Tolerability, immunogenicity and clinical response will also be measured as described in the protocol.

.

 Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma@highlight

The purpose of this study is to determine the safety and tolerability of PVX-410, (a cancer vaccine), treatment regimen for patients with smoldering multiple myeloma as a single agent and in combination with lenalidomide.

